← Back

Grifols SA ADR

7.31-26.1%1Y · USD

Grifols, S.A. researches, develops, produces, and markets plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers hemoderivatives from human plasma for areas such as immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology, and markets diagnostic testing equipment and reagents. It also provides biological products and healthcare solutions for hospitals, and was founded in 1909 with headquarters in Barcelona, Spain.

Country
Price · split & dividend adjusted
News & notes moving GRFS
CanadaSpain
GRFS▼

Union demands permanent end to for-profit plasma collection

The union representing Canadian Blood Services workers in Ontario is calling for an immediate termination of the blood-plasma collection contract with for-profit Spanish pharmaceutical company Grifols. OPSEU/SEFPO is also demanding an ironclad commitment that blood and plasma services are never again operated on a for-profit basis. Two people died after donating plasma at Grifols-operated facilities in Winnipeg in October 2025 and January 2026, and Health Canada data indicates at least 25 serious adverse reactions have been reported at Grifols clinics since 2018. This week, Health Canada issued a non-compliance rating to Grifols following an inspection of one of its Winnipeg sites, and Grifols announced on August 13 that it is pausing all plasma collection in Canada effective August 14. The union says the pause does not go far enough and wants the contract cancelled immediately, citing non-compliant ratings at Grifols facilities in Ontario, New Brunswick, Saskatchewan, and Alberta for issues including improper donor screening and equipment maintenance.
GRFS ▼
GRFS · Regulation · Negative Health Canada issued a non-compliance rating to Grifols after inspecting a Winnipeg plasma site, and the union is demanding cancellation of its for-profit plasma contract amid deaths and adverse reactions.
Read original ↗
GlobeNewswire·51dRead more →
Biotech & Genomic Medicine▲2

Grifols Reports First-Half 2026 Revenue of €3.574 Billion, Maintains Full-Year Guidance

Grifols reported first-half 2026 revenue of €3.574 billion, a 2.6% increase at constant currency, and maintained its full-year free cash flow guidance of $500 million to $575 million. Biopharma revenue grew 5.4% at constant currency, driven by a 12.8% rise in the immunoglobulin franchise, while Xembify revenue surged nearly 34% in the second quarter. Adjusted EBITDA reached €854 million for the half, with a margin of 23.9%, and free cash flow before M&A improved by €103 million year-over-year to €91 million. The company closed 29 U.S. donor centers, incurring $40 million in one-off costs, and is expanding plasma sourcing in Egypt, which now supplies 25% of ex-U.S. collections with a target of 50% by 2029. Management also confirmed the SPARTA Phase 3 study for Alpha-1 remains on track for top-line results in late Q4 2026.
GRFS ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Plasma-Derived & Blood Products ▲Supply
GRFS · Capital · Positive Grifols reported H1 2026 revenue of €3.574B (+2.6% cc), adjusted EBITDA of €854M, and maintained full-year free cash flow guidance of $500-575M.
GRFS · Demand · Positive Biopharma revenue grew 5.4% cc on a 12.8% rise in the immunoglobulin franchise and Xembify revenue up nearly 34% in Q2.
Read original ↗
The Motley Fool·68dRead more →
Biotech & Genomic Medicine▲

Grifols Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency

Grifols launched FESILTY in the United States for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency, excluding dysfibrinogenemia. The highly purified human-derived fibrinogen concentrate provides a precise, targeted treatment for this rare genetic condition where insufficient clotting proteins compromise wound healing. Compared to traditional options like cryoprecipitate or fresh frozen plasma, FESILTY allows for faster, more predictable dosing without needing large-volume infusions or cross-matching. It comes in a complete kit that can be stored at room temperature and reconstituted in approximately three minutes, making it effective for time-sensitive bleeding events. FDA approval was supported by Phase I/III clinical study data confirming safety, pharmacokinetic properties, and hemostatic efficacy, though the product carries risks including potential hypersensitivity and thrombotic events and is contraindicated in patients with severe hypersensitivity to its components.
GRFS ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Rare Disease ▲Supply
Biotech & Genomic Medicine › Plasma-Derived & Blood Products ▲Supply
GRFS · Technology · Positive Grifols launched FESILTY in the U.S., a new FDA-approved fibrinogen concentrate product for congenital fibrinogen deficiency.
Read original ↗
Insider Monkey·108dRead more →
© 2026 MarketDXAsset